Design Therapeutics, Inc.
NASDAQ:DSGNBiotechnology
+$0.19 today
- Market cap
- $606.42M
- Beta
- 1.66
- P/E (TTM)
- -10.7
- EPS (TTM)
- -$1.13
Volume 0.32M
Average 0.74M
DSGN EBITDA Margin
EBITDA as a percentage of revenue.
Design Therapeutics, Inc.NASDAQ: DSGN
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin not reported for Q1 FY2026
Sources:Income StatementText generated from reported figures; not investment advice.
EBITDA Margin history
Percent of revenue · from the income statement
No EBITDA Margin data reported for this period type.
EBITDA Margin vs competitors
How DSGN compares with its peers on the latest reported figures
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 17.2% | -30.5 pp | +103.9 pp | |
| LTM Mar 2026 | 5.7% | +10.5 pp | +34.3 pp | |
| LTM Sep 2026 | -49.3% | -33.5 pp | +8.7 pp | |
| LTM Mar 2026 | -243.2% | -144.4 pp | +3681.3 pp | |
| LTM Mar 2026 | -511.5% | -539.6 pp | +799.5 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding DSGN) | -49.3% | -33.5 pp | +103.9 pp | |
Competitors are the stored peer set for DSGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 466K | 537K | 596K | 622K |
| Gross Profit | 0 | (466K) | (537K) | (596K) | (622K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 24.78M | 48.61M | 57.06M | 44.35M | 59.13M |
| Selling, General & Admin | 11.05M | 18.98M | 21.13M | 18.03M | 20.34M |
| Operating Expenses | 35.83M | 67.13M | 77.65M | 61.79M | 78.85M |
| Depreciation & Amortization | 129K | 466K | 537K | 596K | 622K |
| EBITDA | (35.4M) | (62.84M) | (66.33M) | (48.99M) | (69.17M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (35.83M) | (67.59M) | (78.19M) | (62.38M) | (79.47M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 12.8M | 9.68M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 298K | 4.29M | 11.33M | 12.8M | 9.68M |
| Income Before Tax | (35.53M) | (63.31M) | (66.86M) | (49.59M) | (69.79M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (35.53M) | (63.31M) | (66.86M) | (49.59M) | (69.79M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.77) | (1.14) | (1.19) | (0.88) | (1.22) |
| EPS (Diluted) | (0.77) | (1.14) | (1.19) | (0.88) | (1.22) |
| Weighted Avg Shares | 45.94M | 55.71M | 55.98M | 56.59M | 57.33M |
| Weighted Avg Shares (Diluted) | 45.94M | 55.71M | 55.98M | 56.59M | 57.33M |
Design Therapeutics, Inc.
NASDAQ:DSGN
Intrinsic Alpha fair value
Locked
Current Price
$9.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.